These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8529515)

  • 1. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
    Gries FA
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S201-7. PubMed ID: 8529515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?
    Boel E; Selmer J; Flodgaard HJ; Jensen T
    J Diabetes Complications; 1995; 9(2):104-29. PubMed ID: 7599349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of diabetic neuropathy].
    Uesaka Y
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():256-9. PubMed ID: 12430238
    [No Abstract]   [Full Text] [Related]  

  • 4. The pharmacology of diabetic complications.
    Altan VM
    Curr Med Chem; 2003 Aug; 10(15):1317-27. PubMed ID: 12871132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
    Costantino L; Rastelli G; Vianello P; Cignarella G; Barlocco D
    Med Res Rev; 1999 Jan; 19(1):3-23. PubMed ID: 9918192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological prevention of late complications of diabetes].
    Jensen TJ; Hilsted JC
    Ugeskr Laeger; 1996 Apr; 158(17):2402-3. PubMed ID: 8685997
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies.
    Cameron NE; Cotter MA
    Diabet Med; 1993; 10(7):593-605. PubMed ID: 8403819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus].
    Kakhnovskiĭ IM; Koroleva TV; Golubiatnikova GA; Kalinkina MA
    Klin Med (Mosk); 1996; 74(3):56-8. PubMed ID: 8926708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.
    Cumbie BC; Hermayer KL
    Vasc Health Risk Manag; 2007; 3(6):823-32. PubMed ID: 18200803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
    Calcutt NA; Freshwater JD; Mizisin AP
    Diabetologia; 2004 Apr; 47(4):718-24. PubMed ID: 15298349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
    Bonnefont-Rousselot D
    J Soc Biol; 2001; 195(4):391-8. PubMed ID: 11938556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship.
    Nicolle E; Souard F; Faure P; Boumendjel A
    Curr Med Chem; 2011; 18(17):2661-72. PubMed ID: 21568900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of protein kinase Cbeta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism.
    Cameron NE; Cotter MA
    Diabetes Metab Res Rev; 2002; 18(4):315-23. PubMed ID: 12203947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
    Huang Q; Liu Q; Ouyang D
    Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase in diabetic microvascular complications.
    Chung SS; Chung SK
    Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroxanthyletin-type coumarins from Angelica decursiva that inhibits the formation of advanced glycation end products and human recombinant aldose reductase.
    Ali MY; Jung HA; Jannat S; Choi JS
    Arch Pharm Res; 2018 Feb; 41(2):196-207. PubMed ID: 29230690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyphenols of Myrica faya inhibit key enzymes linked to type II diabetes and obesity and formation of advanced glycation end-products (in vitro): Potential role in the prevention of diabetic complications.
    Spínola V; Llorent-Martínez EJ; Castilho PC
    Food Res Int; 2019 Feb; 116():1229-1238. PubMed ID: 30716910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.